Rimonabant: marketing authorization suspended... at last: withdrawal. Half-measures.
Marketing authorization was granted for rimonabant on the basis of shaky data and despite poorly documented dangers. It took the EMEA 2 years to take action, by advising practitioners not to prescribe this drug.
D019440:Anti-Obesity Agents; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids / Q000037:antagonists & inhibitors; D000075202:Contraindications; D017277:Drug Approval; D005060:Europe; D006801:Humans; D008389:Marketing of Health Services; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D019440:Anti-Obesity Agents; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles